Nanobiopolymer for Direct Targeting and Inhibition of EGFR Expression in Triple Negative Breast Cancer

@inproceedings{Inoue2012NanobiopolymerFD,
  title={Nanobiopolymer for Direct Targeting and Inhibition of EGFR Expression in Triple Negative Breast Cancer},
  author={Satoshi Inoue and Rameshwar Patil and Jos{\'e} Portilla-Arias and Hui Ding and Bindu Konda and Andres Espinoza and Dmitriy Mongayt and Janet L. Markman and Adam Elramsisy and H. Westley Phillips and Keith L. Black and Eggehard Holler and Julia Y. Ljubimova},
  booktitle={PloS one},
  year={2012}
}
Treatment options for triple negative breast cancer (TNBC) are generally limited to cytotoxic chemotherapy. Recently, anti-epidermal growth factor receptor (EGFR) therapy has been introduced for TNBC patients. We engineered a novel nanobioconjugate based on a poly(β-L-malic acid) (PMLA) nanoplatform for TNBC treatment. The nanobioconjugate carries anti-tumor nucleosome-specific monoclonal antibody (mAb) 2C5 to target breast cancer cells, anti-mouse transferrin receptor (TfR) antibody for drug… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
17 Extracted Citations
47 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 17 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 47 references

Similar Papers

Loading similar papers…